Renova Therapeutics Selects Worldwide Clinical Trials

Article

Renova Therapeutics has announced the selection of Worldwide Clinical Trials as its CRO for an upcoming gene therapy study.

Renova Therapeutics has announced the selection of Worldwide Clinical Trials as its CRO for an upcoming gene therapy study. Worldwide Clinical Trials will support the Phase III study of RT-100 AC6 gene transfer for the treatment of patients with reduced ejection fraction heart failure.

Read the full release here

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.